DDR1 and neoplasm: Previously Merestinib (LY2801653; inhibiting DDR1/2 and MET, MST1R, FLT3, AXL, MERTK, TEK, ROS1, and MKNK1/2) has shown potent anti-tumor activity in clinical trials against multiple advanced cancers (Yan et al., 2013).